Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time.
This Phase I/Ila dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.
Adults aged 18-64 years with T2DM, BMI 25-35 kg/m2
On stable Semaglutide 1 mg weekly and for at least 3 months
HbA1c <8%, eGFR≥60 ml/minute
For women: either non-childbearing potential or agreement to use acceptable contraception
Participation in another investigational drug clinical study within 3 months
History of cardiovascular or cerebrovascular disease
Neuropathy or retinopathy or macular edema necessitating medical treatment
Type 1 diabetes